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Background: In the last years, circulating matrix metalloproteinases (MMP)-9 levels have been associated with functional
outcome in ischemic stroke patients. However the prognostic value of circulating levels of tissue inhibitor of matrix
metalloproteinases (TIMP)-1 and MMP-10 in functional outcome of ischemic stroke patients has been scarcely studied.
In addition, to our knowledge, serum MMP-9, MMP-10 and TIMP-1 levels in patients with malignant middle cerebral artery
infarction (MMCAI) for mortality prediction have not been studied, and these were the objectives of this study.
Methods: This was a multicenter, observational and prospective study carried out in six Spanish Intensive Care Units.
We included patients with severe MMCAI defined as Glasgow Coma Scale (GCS) lower than 9. We measured circulating
levels of MMP-9, MMP-10, TIMP-1, in 50 patients with severe MMCAI at diagnosis and in 50 healthy subjects. Endpoint was
30-day mortality.
Results: Patients with severe MMCAI showed higher serum levels of MMP-9 (p = 0.001), MMP-10 (p < 0.001), and TIMP-1
(p = 0.02) than healthy subjects. Non-surviving MMCAI patients (n = 26) compared to survivor ones (n = 24) showed higher
circulating levels of TIMP-1 (p < 0.001), MMP-10 (p = 0.02) and PAI-1(p = 0.02), and lower MMP-9 levels (p = 0.04). Multiple
binomial logistic regression analysis showed that serum TIMP-1 levels > 239 ng/mL are associated with 30-day mortality
(OR = 5.82; 95 % CI = 1.37-24.73; P = 0.02) controlling for GCS and age. The area under the curve for TIMP-1 as predictor of
30-day mortality was 0.81 (95 % CI = 0.67-0.91; P < 0.001). We found an association between circulating levels of TIMP-1
and MMP-10 (rho = 0.45; P = 0.001), plasminogen activator inhibitor (PAI)-1 (rho = 0.53; P < 0.001), and tumor necrosis
factor (TNF)-alpha (rho = 0.70; P < 0.001).
Conclusions: The most relevant and new findings of our study, were that serum TIMP-1 levels in MMCAI patients were
associated with mortality, and could be used as a prognostic biomarker of mortality in MMCAI patients.
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Ischemic stroke is an important cause of disability,
mortality and resources consume [1]. Matrix metallo-
proteinases (MMPs) are implicated in degradation and
remodelling of the extracellular matrix (ECM). That
family of zinc-containing endoproteinases can be
classified according to the substrate specificity as colla-
genases (MMP-1, −8 and −13), gelatinases (MMP-2 and
−9), stromelysins (MMP-3, −10, −11), matrilysins (MMP-
7), elastases (MMP-12) and membrane-type (MT-MMPs,
MMP-14, −15, −16 and −17). MMP activity is regulated
by specific tissue inhibitors of matrix metalloproteinases
(TIMPs). MMPs are involved in physiological functions
such as morphogenesis, menstrual cycle, tissue remodel-
ling and angiogenesis; and also in some diseases with ab-
normal ECM turnover, such as arthritis, sepsis, tumour
invasion and atherosclerosis [2–7].
In the last years, MMPs have been found to play a role
in cerebral ischemia [8–10]. In some studies higher cir-
culating MMP-9 levels were found in ischemic stroke
patients than in controls [11–15], and in ischemic stroke
patients with worse functional outcome [11–19]. How-
ever the prognostic value of circulating levels of TIMP-1
[20] and MMP-10 [21] in functional outcome of ische-
mic stroke patients has been scarcely studied. Circulat-
ing TIMP-1 levels have been associated with poor
prognosis in a community-based cohort of elderly men
risk [22], patients with coronary artery disease [23], and
in different cancer types, such as lung [24] breast [25]
colorectal [26] and gastric cancer [27]. There have been
found higher TIMP-1 concentrations in infarcted brain
tissue compared to healthy cerebral areas [28], higher
expression of TIMP-1 in monocytes of ischemic stroke
patients than in healthy controls [29], and higher circulat-
ing TIMP-1 levels in ischemic stroke patients than in
healthy controls [30–33]. In addition, there has been found
an association between serum TIMP-1 levels and mortality
in patients with severe trauma brain injury [34].
To our knowledge, serum MMP-9, MMP-10 and TIMP-1
levels in patients with malignant middle cerebral artery in-
farction (MMCAI) for mortality prediction have not been
studied, and these were the objectives of this study.
Methods
Design and subjects
This is a multicenter, observational, prospective study
carried out in 6 Intensive Care Units of Spain. The study
was approved by the Institutional Review Board of the 6
participant hospitals: Hospital Universitario de Canarias
(La Laguna, Santa Cruz de Tenerife, Spain), Hospital Uni-
versitario Nuestra Señora de Candelaria (Santa Cruz de
Tenerife, Spain), Hospital General de La Palma (La Palma,
Spain), Hospital Clínico Universitario de Valencia (Valencia,
Spain), Hospital Insular (Las Palmas de Gran Canaria,Spain), Hospital Universitario Dr. Negrín (Las Palmas de
Gran Canaria, Spain). The written informed consent from
the patients or from their legal guardians was obtained.
We included 50 patients with severe MMCAI and 50
healthy volunteer control subjects. Severity of MMCAI was
classified according to Glasgow Coma Scale (GCS) [35],
and severe was defined as GCS ≤ 8. Exclusion criteria were:
age less than 18 years, inflammatory or malignant disease.
Variables recorded
The following variables were recorded for each patient:
sex, fibrinolityc therapy, decompressive craniectomy, age,
temperature, sodium, glycemia, leukocytes, pressure of ar-
terial oxygen (PaO2), PaO2/ pressure of arterial oxygen/
fraction inspired oxygen (FI02) ratio, bilirubin, creatinine,
hemoglobin, GCS, lactic acid, platelets, international nor-
malized ratio (INR), activated partial thromboplastin time
(aPTT), fibrinogen, Acute Physiology and Chronic Health
Evaluation II (APACHE II) score [36]. The end-point of
the study was 30-days mortality.
Blood sample collection
Blood samples of 50 patients with severe MMCAI were
collected at the moment of the diagnosis and of 50
controls to measure the concentrations of MMP-9,
MMP-10, TIMP-1, tumor necrosis factor (TNF)-alpha,
and plasminogen activator inhibitor (PAI)-1. To avoid
the possible dispersion of serum level results, all the
samples were processed at same time and in the same
laboratory, at the end of the recruitment process.
Determination of serum MMP-9, MMP-10, TIMP-1 and
TNF-alpha levels
Serum separator tubes were used to determine serum
MMP-9, MMP-10, TIMP-1 and TNF-alpha levels. Ven-
ous blood samples were taken and centrifuged within
30 min at 1000 g for 15 min, and the serum was re-
moved and frozen at −80 °C until measurement.
MMP-9, MMP-10 and TIMP-1 assays were performed
at the Atherosclerosis Research Laboratory of CIMA-
University of Navarra (Pamplona, Spain) and were assayed
by specific ELISAs (Quantikine®, R&D Systems, Abingdon,
United Kingdom) according to the manufacturer's instruc-
tions with a serum dilution of 1:80, 1:2 and 1:100 respect-
ively. The interassay coefficients of variation (CV) were
<8 % (n = 20) and detection limit for the assays were
0.31 ng/ml, 78.1 pg/ml and 0.15 ng/ml respectively.
TNF-alpha serum levels were measured in the Laboratory
Deparment of the Hospital Universitario de Canarias (La
Laguna, Santa Cruz de Tenerife, Spain) by a solid-phase,
chemiluminiscents immunometrics assays kit (Immulite®,
Siemens Healthcare Diagnostics Products, Llanberis,
United Kingdom); and the interassays CV was <6.5 %
(n = 20) and detection limit for the assay was 1.7 pg/mL.
Table 2 Clinical and biochemical characteristics of survivor and
non-survivor MMCAI patients
Survivors
(n = 24)
Non-survivors
(n = 26)
P
value
Gender female – n (%) 8 (33.3) 9 (34.6) 0.99
Decompressive
craniectomy – n (%)
7 (29.2) 5 (19.2) 0.51
Age (years) - median
(p 25–75)
47 (32–67) 66 (45–76) 0.14
Temperature (°C) -
median (p 25–75)
36.5 (35.7-37.0) 37.0 (35.7-37.8) 0.26
Sodium (mEq/L)- median
(p 25–75)
140 (138–145) 140 (137–146) 0.91
Glycemia (g/dL) - median
(p 25–75)
133 (105–170) 135 (110–154) 0.92
Leukocytes-median*103/
mm3 (p 25–75)
12.8 (9.8-16.9) 14.4 (11.9-21.9) 0.49
PaO2 (mmHg) - median
(p 25–75)
110 (101–194) 104 (85–139) 0.10
PaO2/FI02 ratio - median
(p 25–75)
246 (192–327) 248 (175–320) 0.41
Bilirubin (mg/dl) - median
(p 25–75)
0.50 (0.38-0.90) 0.53 (0.30-1.20) 0.76
Creatinine (mg/dl) - median
(p 25–75)
0.80 (0.60-1.10) 1.01 (0.85-1.45) 0.052
Hemoglobin (g/dL) - median
(p 25–75)
12.0 (11.3-13.8) 12.0 (11.0-15.1) 0.92
GCS score - median
(p 25–75)
7 (6–8) 6 (4–8) 0.10
Lactic acid (mmol/L)-median
(p 25–75)
1.25 (0.93-1.68) 1.50 (1.01-3.15) 0.08
Platelets - median*103/mm3
(p 25–75)
227(183–308) 152 (123–190) 0.003
INR - median (p 25–75) 1.07 (1.01-1.20) 1.20 (1.07-1.48) 0.16
aPTT (seconds) - median
(p 25–75)
28 (25–29) 26 (25–33) 0.96
Fibrinogen (mg/dl) -
median (p 25–75)
440 (335–494) 409 (322–598) 0.71
APACHE-II score - median
(p 25–75)
20 (16–25) 22 (19–29) 0.14
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Venous blood samples were collected in citrate collected
plasma tubes and centrifugedwithin 30 min at 1000*g for
15 min. The plasma was removed and frozen at −80 °C
until measurement. PAI-1 assay was performed at the
Laboratory Department of the Hospital Universitario de
Canarias (La Laguna, Santa Cruz de Tenerife, Spain).
PAI-1 antigen levels were assayed by specific ELISA
(Imubind Plasma PAI-1 American Diagnostica, Inc,
Stanford, CT, USA). The interassay CV of PAI-1 assay
was <5 % (n = 20) and detection limits was 1 ng/mL.
Statistical methods
Continuous variables are reported as medians and
interquartile ranges. Categorical variables are reported as
frequencies and percentages. Comparisons of continuous
variables between groups were carried out using
Wilcoxon-Mann–Whitney test. Comparisons between
groups on categorical variables were carried out with
chi-square test.
Multiple binomial logistic regression analysis was applied
to determine the independent contribution of TIMP-1 on
30-day mortality, controlling for GCS and age. Odds Ratio
and 95 % confidence intervals were calculated as measure-
ment of the clinical impact of the predictor variables.
Receiver operating characteristic (ROC) analysis was
carried out to determine the goodness-of-fit of the of
serum TIMP-1 levels to predict 30-day mortality.
Kaplan-Meier analysis of survival at 30 days and com-
parisons by log-rank test were carried out using serum
TIMP-1 levels lower/higher than 239 ng/mL as the
independent variable and survival at 30 days as the
dependent variable. The association between continuous
variables was carried out using Spearman’s rank correl-
ation coefficient. A P value of less than 0.05 was consid-
ered statistically significant. Statistical analyses were
performed with SPSS 17.0 (SPSS Inc., Chicago, IL, USA)
and NCSS 2000 (Kaysville, Utah) and LogXact 4.1, (Cytel
Co., Cambridge, MA).Table 1 Characteristics of healthy controls and patients with
severe MMCAI
Healthy controls
(n = 50)
Patients (n = 50) p-value
Gender female – n (%) 13 (26.0 %) 17 (34 %) 0.51
Age (years) - median
(p 25–75)
57 (50–63) 60 (51–69) 0.11
TIMP-1 (ng/mL) - median
(p 25–75)
226 (213–241) 261 (199–387) 0.02
MMP-9 (ng/mL) - median
(p 25–75)
498 (350–735) 749 (488–1200) 0.001
MMP-10 (pg/mL) - median
(p 25–75)
466 (288–614) 1027 (556–1409) <0.001
MMP = matrix metalloproteinase; TIMP = tissue inhibitor of matrix
metalloproteinases
MMP-9 (ng/mL) - median
(p 25–75)
963 (731–1218) 672 (384–1088) 0.04
MMP-10 (pg/mL) -
median (p 25–75)
785 (550–1114) 1264 (608–1759) 0.02
TIMP-1 (ng/mL) - median
(p 25–75)
204 (172–264) 343 (240–493) <0.001
PAI-1 (ng/mL) - median
(p 25–75)
24.0 (19.3-40.8) 51.5 (28.3-95.3) 0.02
TNF-alpha (pg/mL) -
median (p 25–75)
9.25 (9.02-
10.63)
12.95 (10.03-
15.08)
0.01
P 25-75 = percentile 25th-75th; PaO2 = pressure of arterial oxygen/fraction inspired
oxygen; FIO2 = pressure of arterial oxygen/fraction inspired oxygen; GCS =Glasgow
Coma Scale; ISS = Injury Severity Score; INR = international normalized ratio;
aPTT = activated partial thromboplastin time; APACHE II = Acute Physiology and
Chronic Health Evaluation; MMP=matrix metalloproteinase; TIMP = tissue inhibitor
of matrix metalloproteinases; PAI = plasminogen activator inhibitor; TNF = tumor
necrosis factor
Fig. 1 Receiver operation characteristic analysis using TIMP-1 serum
levels as predictor of mortality at 30 days
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Patients with severe MMCAI showed higher serum
levels of MMP-9, MMP-10 and TIMP-1 than healthy
subjects (Table 1).
We found that non-surviving MMCAI patients (n = 26)
compared to survivors ones (n = 24) showed higher circu-
lating levels of MMP-10, TIMP-1, PAI-1 and TNF-alpha,
and lower MMP-9 levels (Table 2).
Multiple binomial logistic regression analysis showed
that serum TIMP-1 levels > 239 ng/mL are associated
with 30-day mortality (OR = 5.82; 95 % CI = 1.37-24.73;
P = 0.02) controlling for GCS and age (Table 3).
The area under the curve (AUC) for TIMP-1 as pre-
dictor of 30-day mortality was 0.81 (95 % CI = 0.67-0.91;
P < 0.001) (Fig. 1).
Survival analysis showed that patients with serum
TIMP-1 higher than 239 ng/mL presented higher 30-day
mortality than patients with lower levels (Hazard ratio =
3.6; 95 % CI = 1.67-7.82; P = 0.004) (Fig. 2).
We found an association between circulating levels of
TIMP-1 and MMP-10 (rho = 0.45; P = 0.001), PAI-1 (rho =
0.53; P < 0.001), and TNF-alpha (rho = 0.75; P < 0.001).
Discussion
The novel findings of our study were the following: a)
non-surviving severe MMCAI patients had higher serum
TIMP-1 and MMP-10 levels than surviving patients; b)
there is an association between circulating levels of
TIMP-1, PAI-1, and TNF-alpha in patients with severe
MMCAI; c) serum TIMP-1 levels could be used as prog-
nostic biomarker in patients with severe MMCAI.
We found that patients with severe MMCAI showed
higher serum levels of MMP-9, MMP-10 and TIMP-1 than
healthy subjects. Previously there were found higher circulat-
ing levels of MMP-9 [11–15] and MMP-10 [21] and TIMP-
1 [30–33] in ischemic stroke patients than in controls. In
addition, there have been found higher production of TIMP-
1 in infarcted brain tissue compared to healthy brain areas
[28], and higher expression of TIMP-1 in monocytes of is-
chemic stroke patients than in healthy controls [29].
In addition, we found higher circulating MMP-10 and
TIMP-1 levels, and lower circulating MMP-9 levels in
non-surviving severe MMCAI patients than in surviving
patients. The findings in respect to MMP-10 are in con-
sonance with a previous study showing an association
between serum MMP-10 and functional outcome inTable 3 Multiple binomial logistic regression analysis to predict
30-day mortality
Variable Odds Ratio 95 % Confidence Interval P
TIMP-1 > 239 ng/mmL 5.82 1.37-24-73 0.02
GCS score 0.79 0.56-1.12 0.19
Age (years) 1.01 0.95-1.07 0.81ischemic stroke patients [21]; however, in our current
study, we found for the first time higher serum MMP-10
in non-surviving than in surviving MMCAI patients.
Our findings, showing higher TIMP-1 levels in non-
surviving severe MMCAI patients than in surviving pa-
tients, could be in agreement with the results of other
previous study [20]. A relationship between plasma
TIMP-1 levels at 7 days of clinical ischemic with neuro-
logical clinical outcome has been demonstrated [20].
Then, another new finding of our study were those higher
serum TIMP-1 levels at moment of severe MMCAI diagno-
sis in non-survivor than in survivor patients. Previously,Fig. 2 Survival curves at 30 days using TIMP-1 serum levels higher or
lower than 239 ng/mL
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TIMP-1 levels and poor prognosis in elderly men [22], pa-
tients with coronary artery disease [23], patients with differ-
ent types of cancer [24–27], and patients with severe
trauma brain injury [34].
On the other hand, the results regarding to circulating
MMP-9 levels are in contradiction with those previously
published reporting a poor functional outcome with high
circulating MMP-9 levels [11–19].
Another interesting new findings of our study were
the association between serum TIMP-1 levels and mor-
tality in logistic regression analysis, and the mortality
prediction of circulating TIMP-1 levels according to the
ROC analysis. These findings agree with the results of a
previous study by our team in patients with severe
trauma brain injury [34].
The pathophysiological role of circulating TIMP-1
levels in MMCAI patients is still unknown. It is possible
that the increased levels in these patients may be due to
an increase of circulating MMP-9 and MMP-2 levels, in
order to maintain the balance between proteases and
inhibitors. Interestingly, we report for the first time an
association between circulating levels of TIMP-1 and
MMP-10, PAI-1, and TNF-alpha in patients with severe
MMCAI patients. Previously higher circulating levels of
PAI-1 [37, 38] and TNF-alpha [21] were found in ische-
mic stroke patients with poor functional outcome. Taken
together, these data suggest that TIMP-1 levels could
play a role in the pathophysiology of MMCAI. It is
possible that increased serum TIMP-1 levels in non-
survivors TBI patients is not the cause of death in these
patients, rather a biomarker associated with mortality.
Some limitations of our study should be recognized. First,
we did not report data about the evolution of TIMPs and
MMPs on the time to describe the evolution in non-
surviving and surviving TBI patients. Second, the determin-
ation of other MMPs and TIMPs would be desirable. Third,
the assessment of other inflammatory cytokines and coagu-
lation biomarker could be interesting. Four, there is overlap
of serum TIMP-1 levels between dead and alive patients at
30 days; thus, the sole use of serum TIMP-1 levels to pre-
dict 30-day survival in MMCAI patients should be taken
with caution. However, we think that the findings of our
study (reporting for the first time an association between
TIMP-1 and mortality in MMCAI patients) could open the
interest for research about TIMP-1 in MMCAI patients.
The administration of modulators of MMP activity have
showed a beneficial effect in rat ischemic stroke models
reducing the expression of MMPs, blood–brain barrier
leakage, volumen infarction, neurological dysfunction and
mortality [39–44]. Thus, from a therapeutic perspective,
MMP activity modulators levels could be used as a new
class of drugs for the treatment of patients with severe is-
chemic stroke.Conclusions
The most relevant and new findings of our study, were
that serum TIMP-1 levels in MMCAI patients were as-
sociated with mortality, and could be used as a prognos-
tic biomarker of mortality in MMCAI patients.
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